GlaxoSmithKline Pulls Tykerb sNDA Ahead Of FDA Panel Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The sponsor withdrew the application for combination use of lapatinib with Roche’s Herceptin in breast cancer less than two weeks before a scheduled advisory committee review, because of questions from FDA “that could not be addressed with the data currently available.” Those questions may have been driven by concerns about the clinical meaningfulness of a four-week median progression-free survival benefit and other efficacy issues.
You may also be interested in...
Tykerb/Herceptin Combination Will Go Before FDA Advisory Panel
FDA’s Oncologic Drugs Advisory Committee will review a combination of GlaxoSmithKline’s Tykerb (lapatinib) with Roche’s Herceptin (trastuzumab) that would offer patients with HER-2 positive metastatic breast cancer a chemo-free option.
GSK Study Shows Tykerb/Herceptin Combo Increases Progression-Free Survival In Breast Cancer
Firm unveils positive Phase III data in women with HER-2 positive metastatic breast cancer weeks ahead of ASCO annual meeting.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.